Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer
G. Thomas Budd, MD
Published Online: Tuesday, June 25, 2013
G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses the background and results of the S0221 trial in breast cancer.
Previously, Budd says, researchers analyzed two dose-dense regimens and found that treatment with doxorubicin-cyclophosphamide followed by paclitaxel given every two weeks was more effective than the same regimen with all drugs given every three weeks.
Another trial looked at the same regimen given weekly and compared it to treatment every three weeks. In this analysis, weekly treatment was better than treatment every three weeks.
In the S0221 trial, researchers compared these two schools of thought, Budd says. The trial showed that in terms of efficacy, these two regimens produced similar outcomes, but the side effects differed.
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today’s patients.
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression